Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD). Click here to learn more.

C3441021 (TALAPRO2)

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC. Click here to learn more.

GT0918-US-1002: Suzhou Kintor Pharmaceutical Inc.

The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer. Click here to learn more.


Learn more about Prostate Cancer >

Our Affiliations


 QCCA The Cancer FoundationNCI

We’re Here to Help! Click Below to Get Started